<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01965509</url>
  </required_header>
  <id_info>
    <org_study_id>PEX168-I-06</org_study_id>
    <nct_id>NCT01965509</nct_id>
  </id_info>
  <brief_title>A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 12 Weeks Injection of Polyethylene Glycol Loxenatide Add to Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1)&#xD;
      analogue that created on the basis of the Exenatide and modified by polyethylene glycol&#xD;
      (PEG).&#xD;
&#xD;
      This study aims to evaluate the effective therapeutic concentration range of PEX168, also&#xD;
      decided to observe safety and PK/PD correlation by long-term continuous administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess HbA1C levels after treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess Fasting blood glucose levels</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the body weights after the treatment</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>To assess number of participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>PEX168 100 microgram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEX168 100 microgram qw sc. and the medication continued for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEX168 200 microgram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEX168 200 microgram qw sc. and the medication continued for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo qw sc. and the medication continued for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEX168 or placebo</intervention_name>
    <description>injection has to administered subcutaneously weekly</description>
    <arm_group_label>PEX168 100 microgram</arm_group_label>
    <arm_group_label>PEX168 200 microgram</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Polyethylene Glycol Loxenatide or Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has been diagnosed with type 2 diabetes mellitus.&#xD;
&#xD;
          2. Has been treated with a stable dose of metformin monotherapy ≥ 12 weeks before&#xD;
             randomization, and metformin dose ≥ 1500 mg / day.&#xD;
&#xD;
          3. Has HbA1c of 7.5% to 11.0%(local) at screening. And has HbA1c of 7.0% to&#xD;
             11.0%(Central) before randomization.&#xD;
&#xD;
          4. Is 20 to 70 years old, inclusive.&#xD;
&#xD;
          5. Has a body mass index (BMI) of 19 kg/m2 to 35 kg/m2, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Skin test of PEX168 is positive.&#xD;
&#xD;
          2. Is currently treated with any of the following excluded medications:&#xD;
&#xD;
               -  GLP-1 or GLP-1 analogues prior to study start;&#xD;
&#xD;
               -  Insulin within 6 months prior to study start;&#xD;
&#xD;
               -  Growth hormone within 6 months prior to study start;&#xD;
&#xD;
               -  Abuse of drug or alcohol within 6 months prior to study start;&#xD;
&#xD;
               -  Any other hypoglycemic drugs (including Chinese herbal medicine) except for&#xD;
                  metformin within 3 months prior to study start;&#xD;
&#xD;
               -  Any clinical trials of drugs or medical instruments within 3 months prior to&#xD;
                  study start;&#xD;
&#xD;
               -  Systemic corticosteroids by oral, parenteral, or intra-articular route&#xD;
&#xD;
               -  Any drugs for weight loss or operations leading to weight instable within 2&#xD;
                  months prior to study start;&#xD;
&#xD;
               -  Any drugs that may interfere the evaluation of safety and efficiency of&#xD;
                  investigated drugs, drugs or herbals medicine that may result in toxicity to main&#xD;
                  organs prior to study start;&#xD;
&#xD;
          3. A history or evidence of any of the following :&#xD;
&#xD;
               -  Severe hypoglycemia history (e.g., sleepiness, consciousness disorder,&#xD;
                  deliration, coma led by hypoglycemia);&#xD;
&#xD;
               -  Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury,&#xD;
                  or secondary forms of diabetes (e.g., Cushing's syndrome or acromegaly-associated&#xD;
                  diabetes);&#xD;
&#xD;
               -  Acute or chronic gastrointestinal diseases that were not suitable for the trials&#xD;
                  evaluated by investigators;&#xD;
&#xD;
               -  Hypertension with SBP&gt;140mmHg, and/or DBP &gt;90mmHg after antihypertensive therapy;&#xD;
&#xD;
               -  Severe cardiovascular diseases histories including congestive heart failure (NYHA&#xD;
                  III or IV), unstable angina, stroke or TIA, myocardial infarction,sustained and&#xD;
                  clinically relevant ventricular arrhythmia, coronary artery bypass surgery or&#xD;
                  percutaneous coronary intervention;&#xD;
&#xD;
               -  Acute or chronic pancreatitis history, or pancreas injury history, or any high&#xD;
                  risk factors which may result in pancreatitis;&#xD;
&#xD;
               -  Malignancy of any organ system (other than localized basal cell carcinoma of the&#xD;
                  skin), treated or untreated, regardless of whether there is evidence of local&#xD;
                  recurrence or metastases;&#xD;
&#xD;
               -  Medullary thyroid carcinoma history, or multiple endocrine neoplasia history;&#xD;
&#xD;
               -  Acute metabolic complications such as ketoacidosis, lactic acidosis, or&#xD;
                  hyperosmolar state (coma) , or maculopathy , or instability of proliferative&#xD;
                  retinopathy within the past 6 months;&#xD;
&#xD;
               -  Weight change is over 10% within 3 months prior to the study start;&#xD;
&#xD;
          4. Any of the following significant laboratory abnormalities:&#xD;
&#xD;
               -  Alanine aminotrasferase (ALT) and/or asparatate aminotransferase (AST)&gt;2*upper&#xD;
                  limit of normal (ULN), and/or total bilirubin&gt;1.5*ULN, confirmed by repeat&#xD;
                  measure;&#xD;
&#xD;
               -  Creatinine &gt; upper limit of normal, confirmed by repeat measure, and/or&#xD;
                  proteinurea&gt;++ and 24 hour urinary protein quantitative ≥1g;&#xD;
&#xD;
               -  Fasting plasma triglyceride ≥ 5.64 mmol/L (500mg/dL);&#xD;
&#xD;
               -  Thyroid dysfunction unsuitable for this trial evaluated by investigator;&#xD;
&#xD;
               -  Hemodlastase &gt; upper limit of normal, confirmed by repeat measure;&#xD;
&#xD;
          5. Male or female fertility are reluctant to take contraceptive method during the test,&#xD;
             pregnancy or lactating women;&#xD;
&#xD;
          6. Any other situations which may result in the withdrawal of subjects or bring&#xD;
             significant risk to subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenying Yang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>October 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2013</study_first_posted>
  <last_update_submitted>October 15, 2013</last_update_submitted>
  <last_update_submitted_qc>October 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PEX168</keyword>
  <keyword>Phase I/II</keyword>
  <keyword>add on to metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

